



# JOINN Laboratories NEWS

昭衍  
JOINN

## Joinn Assists the Successful Launch of Platinum Life's Amymetose Injection

On January 2, 2025, Platinum Life (Beijing) Co., Ltd. (hereinafter, "Platinum Life") announced that Amymetose Injection, its umbilical cord mesenchymal stem cell treatment product, was approved for marketing. Amymetose Injection (trade name: Ruibosheng) is the first stem cell therapy product approved for marketing in China, mainly used to treat acute graft-versus-host disease due to hormonal therapy failure with predominantly gastrointestinal involvement in patients over 14 years old. The launch of this drug demonstrates Platinum Life's capacity in innovative drug research and development, and marks China's significant progress in stem cell therapy.

### National Medical Products Administration

#### **The National Medical Products Administration Conditionally Approves Amymetose Injection for Marketing**

Recently, the National Medical Products Administration conditionally approved Platinum Life's Amymetose Injection (trade name: Ruibosheng) for marketing through its priority review and approval process. Amymetose Injection is used for the treatment of acute graft-versus-host disease in patients over 14 years of age who have failed hormone therapy with mainly gastrointestinal involvement.

Graft-versus-host disease is a multi-organ syndrome that occurs after allogeneic hematopoietic stem cell transplantation when lymphocytes from the donor attack the recipient's tissues. It is shown as tissue inflammation and fibrosis mainly affecting skin, gastrointestinal tract, liver, lungs and mucosal surfaces. Amymetose is an injection of human umbilical cord mesenchymal stem cells. The launch of this product provides a new treatment option for patients.

Graft-versus-host disease (GvHD) is a major complication after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) and a big threat to life that can lead to death. Mesenchymal stem cells (MSC), a type of pluripotent stem cells, are widely used in clinical applications. They can not only improve the success rate of transplantation, but also promote hematopoietic reconstruction, thereby improving the survival rate of patients. The launch of Platinum Life's Amymetose injection provides a new treatment option for this type of disease and is one of the more effective treatment strategies.

Joinn is honored to assist Platinum Life in successfully launching Amymetose injection. We were responsible for the non-clinical effectiveness and safety evaluation of the drug. With 30 years of experience in preclinical evaluation of cell therapy, Joinn has established a complete animal testing platform for preclinical safety evaluation, and can provide comprehensive evaluation services for cell therapies. Joinn has participated in the preclinical evaluation of a number of stem cell and immune cell therapy products in China, including Amymetose injection (the first stem cell therapy product in China), and preclinical research on TCR-T cells



and neoantigens T cell therapy products that were the first in China to obtain registration clinical approval. Joinn has always adhered to its mission of “serving drug innovation and focusing on safety evaluation and monitoring of the entire life cycle of drugs”, and is committed to providing services and solutions across the entire life cycle for global drug research and development, ensuring patient drug safety and safeguarding the health of humankind!

#### **About Platinum Life**

Platinum Life, registered in Beijing in May 2010, is a high-tech company dedicated to the research and development of innovative stem cell drugs. The company has always been driven by innovation and oriented towards industrialization, focusing on foundational research and clinical transformation and application of stem cells. After more than ten years of unremitting efforts, the “Human Umbilical Cord Mesenchymal Stem Cell Injection” treatment project for aGVHD was approved by CDE to carry out phase II clinical trials in February 2020, making it the first Chinese company to register and apply for intravenous injection through licensing clinical research projects on new stem cell drugs for drug delivery. It strives to become the first new stem cell drug approved for marketing in Beijing and even in China, which will fill the gap in China and allow stem cell drug treatment to benefit thousands of people and families. At the same time, it has important significance for the “Healthy China” strategic goal of China.

昭衍  
JOINN